224 related articles for article (PubMed ID: 29269934)
1. The expression of AURKA is androgen regulated in castration-resistant prostate cancer.
Kivinummi K; Urbanucci A; Leinonen K; Tammela TLJ; Annala M; Isaacs WB; Bova GS; Nykter M; Visakorpi T
Sci Rep; 2017 Dec; 7(1):17978. PubMed ID: 29269934
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
3.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
5. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
9. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
10. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
11. Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor.
Cai Y; Chen M; Gong Y; Tang G; Shu Z; Chen J; Zhou H; He Y; Long Z; Gan Y
Clin Transl Med; 2024 Jan; 14(1):e1531. PubMed ID: 38214432
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
13. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
14. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase.
Jathal MK; Siddiqui S; Vasilatis DM; Durbin Johnson BP; Drake C; Mooso BA; D'Abronzo LS; Batra N; Mudryj M; Ghosh PM
J Biol Chem; 2023 Aug; 299(8):104973. PubMed ID: 37380074
[TBL] [Abstract][Full Text] [Related]
16. [The concept and mechanisms of castration-resistant prostate cancer].
Naito S; Shiota M
Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
[TBL] [Abstract][Full Text] [Related]
17. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
18. Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer.
Jones D; Noble M; Wedge SR; Robson CN; Gaughan L
Sci Rep; 2017 Feb; 7():40957. PubMed ID: 28205582
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.
Ta HQ; Ivey ML; Frierson HF; Conaway MR; Dziegielewski J; Larner JM; Gioeli D
Cancer Res; 2015 Dec; 75(23):5093-105. PubMed ID: 26573794
[TBL] [Abstract][Full Text] [Related]
20. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]